Long-Term Follow-Up of MonumenTAL-1

Opinion
Video

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

Video content above is prompted by the following:

  • Please discuss the efficacy data, focusing on PFS and DOR, presented at EHA 2024 on the long-term follow-up results of the phase 1/2 MonumenTAL-1 study of talquetamab in patients with RRMM.
    • What factors might contribute to the longer DOR with Q2W dosing compared to QW dosing in patients naive to prior TCR?
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.
A panel of 5 experts on multiple myeloma
Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.
Surbhi Sidana, MD, discussed outpatient supportive care for patients following immunotherapy treatment for hematologic cancers.
Related Content
Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Referrals From Community to Academia Enhances Multiple Myeloma Outcomes

Samer A. Al'Hadidi, MD;Frits van Rhee, MD, PhD;Appalanaidu Sasapu, MD
September 10th 2024
Article

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

ONCOLOGY Staff
August 27th 2024
Article

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD
August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

ONCOLOGY Staff
August 23rd 2024
Article

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.

FDA Gives CRL to Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore;Ariana Pelosci
August 21st 2024
Article

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.